Theresa F O'Keefe

US Patent:

8129130, Mar 6, 2012

Filed:

Mar 18, 2011

Appl. No.:

13/051327

Inventors:

Herren Wu - Boyds MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US
Jane Tian - North Potomac MD, US
Theresa O'Keefe - Waltham MA, US
Shixin Qin - Lexington MA, US

Assignee:

The Feinstein Institute for Medical Research - Manhasset NY
MedImmune, LLC - Gaithersburg MD

International Classification:

G01N 33/53

US Classification:

435 72

Abstract:

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

US Patent:

20090169546, Jul 2, 2009

Filed:

Nov 27, 2006

Appl. No.:

12/094447

Inventors:

Herren Wu - Boyds MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US
Jane Tian - North Potomac MD, US
Theresa O'Keefe - Waltham MA, US
Shixin Qin - Lexington MA, US

Assignee:

MEDIMMUNE, LLC - GAITHERSBURG MD
CRITICAL THERAPEUTICS - LEXINGTON MA

International Classification:

A61K 39/395
C07K 16/00
G01N 33/53
C12Q 1/68
A61P 37/06

US Classification:

4241331, 5303879, 5303873, 4241391, 435 72, 435 6

Abstract:

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.